Study of adults with suspected or confirmed HLH
Treatments studied
Part of Blood & lymphatic clinical trials.
This study follows adults who have findings that suggest HLH, a serious immune problem. It may help doctors better understand the condition by tracking patients over time and comparing symptoms and test results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years old or older
- Have evidence of hemophagocytosis seen on a tissue or bone marrow test, OR meet HLH criteria in another way
- If not found on tissue/bone marrow, you must have at least 3 of the 8 HLH diagnostic criteria
- Be willing to sign a written consent form to join the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is a disease registry that collects medical information from children who have hemophagocytic lymphohistiocytosis (HLH) or are suspected to have it. It helps doctors better understand HLH and how it affects patients over time.
This trial looks at how people with lymphoma-related hemophagocytic lymphohistiocytosis (HLH) respond to treatment. It aims to better describe expected outcomes and who benefits most, which may help guide future care.
This trial tests a combination of a targeted drug (ruxolitinib) with a less intense version of standard chemo for adults with Hemophagocytic Lymphohistiocytosis (HLH). It aims to control the overactive immune response while reducing side effects.
This study is testing a modified treatment regimen (called DEP) with or without the drug ruxolitinib for patients with HLH, a serious condition where the immune system attacks the body. The goal is to see if this combination is safe and helps control the disease.
This study creates a national registry in Egypt to collect information about people with hemophagocytic lymphohistiocytosis (HLH), a rare condition where the immune system becomes overactive and damages the body's own tissues. The goal is to learn more about the disease and improve care.
This trial studies whether giving high-dose cyclophosphamide as an initial treatment works better for adults with HLH. HLH is a serious, overactive immune condition, and the study aims to improve control of the illness and safety.
Hear when a new Hemophagocytic Lymphohistiocytoses trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.